Hygeia
Hygeia is a oncology healthcare company.
Hygeia, founded in 2009 and headquartered in Shanghai, is a provider of oncology medical services. The founder is Zhu Yiwen. Listed on the Hong Kong Stock Exchange on June 29, 2020, the company’s major shareholders are Harmony Healthcare and Fountain Grass. Rivals that have direct and indirect competition with Hygeia include Kangji Medical Holdings Limited, Gan&Lee Pharmaceuticals, Immunotech Biopharm Ltd..
Medtronic's world's first self expanding pulmonary valve was first-class recalled
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Healthcare, Technology, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
Research
Healthcare, Technology, Consumer DiscretionaryLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus
Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU
Upside foods, a cell meat enterprise, received US $400 million in financing, the highest single transaction in the industry
Lingfu biology, an experimental animal research service provider, completed a pre-A round of financing of more than 200 million yuan
Hefei Tiangang immunopharmaceutical Co., Ltd., a tumor immunotherapy enterprise, completed a round of pre-A financing of hundreds of millions of yuan
Ping An Health's 2021 annual report was released, with a revenue of 7.3 billion yuan, a year-on-year increase of 8%
Hong Kong Pharmaceutical stocks plunged straight in the afternoon
Nucleic Acid Drug CDMO Olipharma Raises Tens of Mns of CNY in Pre-Series A Round
As a new way to treat diseases, gene therapy has higher R&D investment and risk than biochemical drugs. Both pharmaceutical giants and start-ups tend to collaborate with outsourcing service providers, which brings business opportunities to cell and gene therapy contract development and manufacturing organizations (CDMOs).
May 18, 2022 09:59 PM
Hillhouse-Backed SMO Stock ClinPlus Climbs 67% on IPO Day
ClinPlus, a Chinese clinic site management company, has completed the initial public offering process and is now the first SMO company to be listed on the Chinese A-share market. After the IPO, Hillhouse is holding 1.5 percent of the company's stock.
May 18, 2022 05:38 AM
"Tiandu technology" won tens of millions of yuan of seed round financing, and AI computing enabled the innovative drug industry
Representative Li Yanping: further improve medical services for the elderly and actively respond to the challenges of aging
The world's first pig heart transplant patient died two months after the operation, and the cause of death is not clear
Gan liming, former vice president of global R & D of AstraZeneca, became president and chief medical officer of global R & D of Ruibo biology